Curcumin for Cholesterol

Verdict: Modest LDL drop, but no substitute for statins

Curcumin produces a small, fairly consistent reduction in LDL and total cholesterol in pooled trials, but the effect is far weaker than statins and no major regulator or lipid society endorses it for cholesterol. Treat it as a marginal add-on at best, not a replacement for proven therapy.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is held at weak/modest because the signal is real but small. Three meta-analyses converge on lower LDL and total cholesterol: an umbrella review of 64 RCTs (PMID 36058763, n=4,187) found LDL down about 7.8 mg/dL and triglycerides down 19 mg/dL, a dose-response meta-analysis (PMID 37230418, n=1,427) showed LDL down roughly 9.9 mg/dL, and a NAFLD meta-analysis (PMID 38232906, n=822) showed LDL down 5.8 mg/dL. Two small low-bias RCTs (PMID 35754684; PMID 31691723) agree, with LDL falling 8 to 12 mg/dL.

What caps the grade is magnitude, consistency, and quality. Effects are strongest in people with diabetes, metabolic syndrome, or fatty liver and weakest in healthy adults; HDL barely moves; and heterogeneity is high (I-squared over 75%) with mostly 8-to-12-week trials. A 6-to-12 mg/dL LDL drop is several-fold smaller than a low-dose statin, so the engine treats it as marginal rather than clinically decisive.

Authorities are split-to-negative, reinforcing caution. NIH/NCCIH says there is not enough evidence to conclude curcumin is beneficial for any health purpose, and Harvard Health states plainly that taking turmeric to lower cholesterol does not make sense; only Cleveland Clinic is cautiously positive, and major lipid societies stay silent. Safety matters too: EFSA set an intake limit of 3 mg/kg/day, and NHS guidance warns to avoid it with gallstones or liver/biliary disease, plus interaction risk with statins and anticoagulants that the target users often take.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.44
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
86%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.37
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.439
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Curcumin as a novel approach in improving lipid profile: An umbrella meta-analysis
PMID: 36058763 2021 統合分析 n = 4,187
Finding: Significant reductions in LDL-C, total cholesterol, and triglycerides; significant increase in HDL-C. Greatest effect with bioavailability-enhanced formulations and durations >8 weeks.
Academic
View on PubMed
Effects of curcumin/turmeric supplementation on lipid profile: A systematic review and dose-response meta-analysis of randomized controlled trials
PMID: 37230418 2023 統合分析 n = 1,427
Finding: Curcumin significantly reduced LDL-C and triglycerides versus placebo. Total cholesterol reduction was significant; HDL-C change was not statistically significant in dose-response analysis.
Academic
View on PubMed
Curcumin supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials
PMID: 38232906 2024 統合分析 n = 822
Finding: Significant reduction in LDL-C and total cholesterol in NAFLD patients. Triglyceride reduction also significant; HDL-C effect modest.
Academic
View on PubMed
Effect of curcumin on lipid profile and glycemic status of patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial
PMID: 35754684 2022 隨機對照試驗 n = 53
Finding: Curcumin significantly reduced LDL-C, total cholesterol, and triglycerides versus placebo. HDL-C increased non-significantly. HbA1c and FBS also improved.
Academic
View on PubMed
Effects of curcumin on cardiovascular risk factors in obese and overweight adolescent girls: A randomized clinical trial
PMID: 31691723 2019 隨機對照試驗 n = 60
Finding: Nano-curcumin significantly reduced LDL-C and total cholesterol versus placebo. Triglyceride reduction was significant; HDL-C did not change significantly. Anthropometric measures also improved.
Academic
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4b EU EFSA
Cautious
the Panel established an ADI for curcumin of 3 mg/kg bw/day source↗
L4c UK NHS
Cautious
Avoid turmeric and curcumin in individuals with bile duct obstruction, cholangitis, liver disease, gallstones, or any biliary disease. source↗
L4d TW TFDA / 衛福部
Cautious
薑黃素每人每日攝取量為每公斤體重0~3毫克,每日不超過200毫克為宜 source↗
L4e WHO
Neutral
Rhizoma Curcumae Longae source↗
L5a NIH Office of Dietary Supplements
Cautious
We don't know enough to definitively conclude if turmeric or curcumin is beneficial for any health purposes. source↗
L5c Cleveland Clinic
Cautious
Curcumin is safe and may protect those at risk for heart disease by lowering certain levels of cholesterol source↗
L5d Harvard Health
Against
Taking cinnamon, garlic, or turmeric to lower cholesterol does not make sense source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cholesterol-INT-curcumin-001 繁體中文版 →